The emerging role of oxaliplatin in the treatment of gastric cancer

Journal of Chemotherapy

Volumn 17, Issue 6, 2005, Pages 656-662

  Zaniboni, Alberto ^a,b   Meriggi, F ^a  

^a Fondazione Poliambulanza   (Italy)

^b NONE   (Italy)

Author keywords

Chemotherapy; Gastric cancer; Oxaliplatin

Indexed keywords

ADENINE; ALKYLATING AGENT; CAPECITABINE; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GUANINE; IRINOTECAN; METHOTREXATE; OXALIPLATIN; PLATINUM DERIVATIVE; RALTITREXED; TEGAFUR; UFT;

ACRAL PARESTHESIA; ADVANCED CANCER; ANEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DNA ADDUCT; DNA REPLICATION; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DYSESTHESIA; ERYTHEMA; FEBRILE NEUTROPENIA; HUMAN; LEUKOPENIA; METASTASIS; NEUTROPENIA; PALMAR PLANTAR ERYTHEMA; PARESTHESIA; PERIPHERAL NEUROPATHY; PROGNOSIS; REVIEW; SENSORY PERIPHERAL NEUROPATHY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA;

EID: 30744440627     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.6.656     Document Type: Review

References (56)

1. th century. Ann Oncol 2003;14 (Suppl 5):V128-V149.
2. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995;333:32-41.
3. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy. Cancer 1998;88:921-932.
4. Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003;39:1603-1609.
5. Scheithauer W, Van Cutsem E. The role of oxaliplatin in the management of upper gastrointestinal tract malignancies. Corectal Dis 2003;5(Suppl 3):36-44.
6. Haller DG. Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers. Semin Oncol 2004; 31 (6 Suppl 14): 10-16.
7. Hoff PM, Fuchs CS. The experience with oxaliplatin in the treatment of upper gastrointestinal carcinomas (Review). Semin Oncol 2003; 30 (4 Suppl 15):54-61.
8. Dickinson JLB, Cunningham D. Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 2004;16:255-63.
9. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric Cancer. Crit Rev Oncol Hematol 2005;54:209-241.
10. Webb A, Cunnigham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
11. Ross P, Nicolson M, Cunningham D et al. Prospective randomized trial comparing mitomycin, cisplatin and protracted venous infusion fluorouracil (PVI 5-FU) with Epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer. JCO 2002;20:1996-2004.
12. Cunningham D, Allum WH, Stenning SP, Weden S, for the NCRI Upper GI Cancer Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol 2005;23:abstract 4001.
13. Ajani JA. Docetaxel for gastric and esophageal carcinomas. Oncology (Huntingt) 2002;16:89-96.
14. Ajani JA, Baker J, Pjsters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastro-esophageal junction carcinoma: results of a phase II study. Cancer 2002;94:641-646.
15. Ajani JA, Van Cutsem E, Moiseyenko V, et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003,22:abstract 999.
16. Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005;23:494-501.
17. st-line advanced gastric cancer patients. Proc Am Soc Clin Oncol 2005;23:abstract 4003.
18. Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicentre phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cancérologie Digestive Group Study-FFCD 9803. J Clin Oncol 2004;22:4319-4328.
19. Souglakos J, Syrigos K, Potamianou A, et al. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann Oncol 2004;15:1204-1209.
20. Raymond E, Faivre S, Woynarowsky JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25:4-12.
21. Bleiberg H, de Gramont A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 1998;25:32-39.
22. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998;9:1053-1071.
23. Eriguchi M, Nonaka Y, Yanagie H, Yoshizaki I, Takeda Y, Sekiguchi M. A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines. Biomed Pharmacother 2003;57:412-415.
24. Trojan J, Kim SZ, Engels K, Kriener S, Mitrou PS, Chow KU. In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer. Anti-Cancer Drugs 2005;16:87-91.
25. Lin WL, Li DG, Chen Q, Lu HM. Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol 2004;10:2911-2915.
26. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Martyn M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303.
27. Louvet C, Andŕ T, Tigaud JM, et ai. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002;20:4543-4548.
28. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004;10:4055-4061.
29. Jin M, Chen Q, Cheng FQ, et al. Oxaliplatin (OXA) in combination with LV5FU2 in Chinese patients with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 2002; 21: abstract 558.
30. Mauer AM, Kraut EH, Rudin CM, et al. Phase II study of oxaliplatin (OX), fluorouracil (FU) and leucovorin (LV) in metastatic carcinoma of the esophagus/gastric cardia. Proc Am Soc Clin Oncol 2002; 21: abstract 554.
31. Bang YJ, Kang YK, Kang WK, et al. Phase II study of oxaliplatin, 5-fluorouracil and folinic acid in recurrent or metastatic gastric cancer. Proc Am Soc Clin Oncol 2002; 21: abstract 2249.
32. Ji JF, Yu Z, Zhong XN, et al. Oxaliplatin-based regimen as neoadjuvant chemotherapy for Chinese patients with advanced gastric cancer: preliminary results of a phase II study. Proc Am Soc Clin Oncol 2004; 23: abstract 4184.
33. Chen JS, Huang JS, Yang TS, et al. Phase I dosing-escalating study of oxaliplatin in combination with oral tegafururacil/leucovorin in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2004; 23: abstract 4266.
34. Cavanna L, Zaniboni A, Artioli F, et al. Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer (A/MGC). Proc Am Soc Clin Oncol 2004; 23: abstract 4068.
35. Chao Y, Chang CJ, Chen LT, et al. Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer 2004; 91: 453-458.
36. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658-663.
37. Pirovano MM, Quinte A, Romanelli A, et al. Chronomodulated delivery schedule of oxaliplatin, 5-fluorouracil and folinic acid as first line treatment for metastatic gastric cancer: toxicity and dose intensity data of a pilot study. Proc Am Soc Clin Oncol 2003; 22: abstract 1214.
38. Petrovic Z, Tarabar D, Doder R, Peric A. Oxaliplatin (L-OHP) and capecitabine (X) as second line chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2003; 22: abstract 1199.
39. Chen JS, Huang JS, Yang TS, et al. Phase I dose escalation study of oxaliplatin combined with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. Anti-Cancer Drugs 2005; 16: 47-51.
40. Santini D, Graziano F, Catalano V, et al. Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC). Proc Am Soc Clin Oncol 2004; 23: abstract 4237.
41. Iop A, Bonura S, Manfredi A, Artioli F. Combination of oxaliplatin, 5-fluorouracil and folinic acid in advanced metastatic gastric carcinoma. Proc Am Soc Clin Ocol 2004; 23; abstract 60.
42. De Vita F, Orditura M, Matano E, et al. A phase II study of biweekly oxaliplatin plus infusional 5-Fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 2005; 26: (Epub ahead of print)
43. Al-Batran SE, Stohlmacher J, Probst S et al. Fluorouracil, leucovorin and oxaliplatin (FLO) as a first line therapy for patients with advanced gastric cancer: First interim analysis of a randomized multicenter phase II study. Proc Am Soc Clin Oncol 2005; 23: abstract 4015.
44. Duyster J, Lorenzen S, Kullmann F et al. Oxaliplatin plus 5-FU/folinic acid (FUFOX regimen) in first-line metastatic gastric cancer (MGC). Results of the multicenter phase II STOMOX trial. Proc Am Soc Clin Oncol 2005; 23: abstract 4016.
45. Catalano V, Graziano F, Salvagni S, et al. Lack of resistance to oxaliplatin (L-OHP)-based chemotherapy in patients (pts) with advanced gastric cancer previously treated with cisplatin-containing regimens: preliminary results of a phase II study. Proc Am Soc Clin Oncol 2002; 21: abstract 2200.
46. Johnson-Barque EJ. Raltitrexed plus oxaliplatin and leucovorin modulated continuous 5-FU infusion (ROLF) in metastatic (MGC) and local advanced (LAGC) gastrointestinal cancer. A phase I/II study. Proc Am Soc Clin Oncol 2004; 23: abstract 4627.
47. Chacón JI, Feliú J, Saenz JAG, et al. Oxaliplatin (Ox) and raltitrexed (RaI) as first line treatment for locally advanced and metastatic gastric adenocarcinoma: results of an ONCO-PAZ phase II trial (OPHA 0141). Proc Am Soc Clin Oncol 2004; 23: abstract 4213.
48. Pan HM, Zhu N, Lou F, et al. A phase II study of oxaliplatin with ELF regimen in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 2004; 23: abstract 4206.
49. Tebbutt N, Norman A, Cunningham D, et al. Randomised, multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in advanced oesophago-gastric cancer; interim analysis. Proc Am Soc Clin Oncol 2002; 21: abstract 523.
50. Sumpter KA, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analysis in a randomized multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer 2005; 92: 1976-83.
51. Erlichman C, Boerner S, Kaufmann SH. Interaction of oxaliplatin with the topoisomerase I inhibitors topotecan and SN-38 (ENG). Ann Oncol 1998; 9 (Suppl 2): 25S.
52. Zeghari-Squalli N, Misset JL, Cvitkovic E et al. Mechanism of the in vitro synergism between SN38 and oxaliplatin (ENG). Proc Am Assoc Cancer Res 1997; 38: 3 (abstract).
53. Bissery MC, Vrignaud P, Lavelle F. In vivo evaluation of the irinotecan-oxaliplatin combination. Proc Am Assoc Cancer Res 1997; 39: 526-527 (abstract).
54. Woell E, Eisterer W, Hilbe W, et al. Oxaliplatin and irinotecan in advanced gastric cancer. A pilot trial. Proc Am Soc Clin Oncol 2003; 22: abstract 1299.
55. Lordick F, Lorenzen S, Stollfuss J, et al. Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer. Br J Cancer 2005; 93: 190-4.
56. Correale P, Fulfaro F, Marsili S, et al. Gemcitabine plus oxaliplatin,folinic acid and 5-fluorouracil (FOLFOX-4)in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2005, July 23 (Epub ahead of print).